EUCTR2008-007667-17-DEActive, not recruitingNot Applicable
Doppelblinde, randomisierte Placebo-kontrollierte crossover-Studie zur Erfassung des Effektes einer DPP-IV-Hemmung auf die Zahl und Funktion von Progenitorzellen sowie die Endothelfunktion von Patienten mit Diabetes mellitusFunctional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus - FINNjA-DM
Dekan des Fachbereichs Medizin der Johann Wolfgang Goethe-Universität Frankfurt/M.0 sitesStarted: April 14, 2009Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •male and female patients with diabetes mellitus type 2 under stable medication,
- •age from 18 to 80 years,
- •HbA1c between 7% an 10%,
- •Signed informed consent,
- •female patients using contraceptions
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Atrial fibrillation (plethysmographic recordings can only obtained in sinus-rhythm),
- •CAD with reduced left ventricular ejection fraction (LVEF <45%),
- •Pregnancy and breast-feeding
- •acute infection or fever,
- •chronic infections like M. Crohn, Rheumatoide Athritis
- •Diabetes mellitus type 1,
- •Newly diagnosed diabetes type 2,
- •uncontrolled diabetes type 2,
- •Neoplasm without documented complete remission in the last 5 years,
- •Known allergy or intolerance to study drug (vildagliptin), lidocain or vasodilatators
- •apoplectic insult in the last 3 month,
- •kidney disease (Kreatinin > 2,5 mg/dl) on the timepoint of treatment
- •Severe liver (GOT > 2x of upper norm value or spontaneous INR > 1,5),
- •HIV infection or aktive Hepatitis
- •Anaemia (Hb <10 mg/dl)
- •Thrombocytopenia < 100.000/µl
- •Participation at other studies within the last 30 days
- •mental retardation
- •any condition that in the opinion of the investigator increases the risk for the patient or excludes the adequat analysis of study data
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Doppelblinde, randomisierte, Placebo-kontrollierte Studie der Phase III zur Bestimmung der Wirksamkeit, Verträglichkeit und Sicherheit von intravesikal verabreichter Oxybutynin-Lösung bei Kindern/Jugendlichen mit neurogen bedingter Detrusorhyperaktivitätbladder disorder (detrusor hyperactivity caused by neurogenic disorder)MedDRA version: 9.1Level: LLTClassification code 10061011Term: <Manually entered code. Term in E.1.1>EUCTR2008-007053-13-DEGrachtenhaus-Apotheke, Inh. Klaus Stegemann e. K.
Active, not recruiting
Phase 1
Studie zur Wirksamkeit und Sicherheit von Ivermectin Tabletten (Driponin®) für die Prophylaxe der COVID-19 ErkrankungCOVID-19 Post-ExpositionsprophylaxeEUCTR2021-002445-15-DEInfectoPharm Arzneimittel und Consilium GmbH412
Completed
Not Applicable
The double blinded, randomized placebo-controlled trial to evaluate the improvement effects of Oligonol ingestion on hidden obesity in healthy women.Hidden obesity of healthy subjectsJPRN-UMIN000018905Wayo Women's University50
Active, not recruiting
Phase 1
Randomiseret, dobbelt blindet placebokontrolleret undersøgelse af subkutan immunglobulinbehandling af kronisk inflammatorisk demyeliniserende polyradikuloneuropati (English: A randomized, double-blinded, placebo controlled trial of subcutaneous infusion of immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy) - Subcutaneous Immunoglobulin in CIDPChronic inflammatory demyelinating polyradiculoneuropathyMedDRA version: 12.0Level: LLTClassification code 10057645Term: Chronic inflammatory demyelinating polyradiculoneuropathyEUCTR2009-013930-25-DKAarhus University Hospital, Department of Neurology30
Active, not recruiting
Not Applicable
Randomisierte, doppelblinde, placebokontrollierte Studie im Parallelgruppen-Design zur Untersuchung der Wirkung von Ginkgo-Spezialextrakt EGb 761® auf Lernprozesse bei gesunden Probandentersuchung der Wirkung von Ginkgo-Spezialextrakt EGb 761® auf Lernprozesse bei Gesunden.EUCTR2005-004476-20-DEDr. Willmar Schwabe GmbH & Co. KG